Navegando por Palavras-chave "Chronic inducible urticaria"

Agora exibindo 1 - 1 de 1
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Update on Omalizumab for Urticaria: What's New in the Literature from Mechanisms to Clinic
    (Current Medicine Group, 2018) Larenas-Linnemann, Desiree E. S.; Parisi, Claudio A. S.; Ritchie, Carla; Cardona-Villa, Ricardo; Cherrez-Ojeda, Ivan; Cherrez, Annia; Ensina, Luis Felipe [UNIFESP]; Garcia, Elizabeth; Medina, Iris V.; Rodriguez-Gonzalez, Mnica; Sanchez Caraballo, Jorge Mario
    Purpose of Review Since omalizumab has been approved for urticaria, numerous randomized and real-life observational trials have been published. We reviewed the period January 2017 February 2018. Recent Findings Omalizumab is effective for the control of urticaria recalcitrant to antihistamines in different populations globally. The ratio of total serum IgE 4-week/baseline >= 2 can predict response with a high likelihood. In observational real-life trials, doses have been adjusted on an individual basis: in some populations, up to two-thirds of the patients can be controlled with 150 mg/ month